Clinical trials: Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
Rifampicin- and Isoniazid-Susceptible Pulmonary Tuberculosis (TB)
A Phase 2 Trial to Evaluate the EBA, Safety and Tolerability of Eto Alone and in Combination With BVL-GSK098
To evaluate the 7-day early bactericidal activity (EBA), pharmacokinetics (PK), safety and tolerability of ethionamide (Eto) with or without BVL-GSK098 in participants with rifampicin- and isoniazid-susceptible pulmonary TB.
- Trial name
- BETO (NCT05473195)
- Testing
- BVL-GSK098 9mg, Ethionamide 250mg, Ethionamide 250 mg
- Where
- South Africa
- Volunteers
- 105 people
- Sponsor
- TASK Applied Science